CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 238 enrolled
Drug / intervention
brimonidine tartrate/timolol fixed combination ophthalmic solution +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01229462
NCT01229462N/ACompleted
CompareCT.gov

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Oct 27, 2010·Updated Sep 14, 2012

In Brief

A clinical study evaluating brimonidine tartrate/timolol fixed combination ophthalmic solution, brimonidine tartrate ophthalmic solution, and 2 other interventions for Glaucoma and Ocular Hypertension. Completed, enrolled 238 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 27, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.7 years ago

Interventions

brimonidine tartrate/timolol fixed combination ophthalmic solutiondrug

One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

brimonidine tartrate ophthalmic solutiondrug

One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

timolol ophthalmic solutiondrug

One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.

fixed combination vehicleother

Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.